LNWTC
INBX icon

Laird Norton Wetherby Trust Company’s Inhibrx INBX Stock Holding History

Laird Norton Wetherby Trust Company’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,382
Closed -$3.19M – 1017
2025
Q4 		$3.19M Buy
+40,382
New +$2.75M 0.07% 227

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Laird Norton Wetherby Trust Company's INBX Position: Q1 2026 in Review

Laird Norton Wetherby Trust Company sold out of Inhibrx (INBX) in Q1 2026, closing a stake of 40,382 shares — an estimated $3.19M sold.

Laird Norton Wetherby Trust Company first reported a position in INBX in Q4 2025 and held it in 1 quarter. The position peaked at $3.19M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Laird Norton Wetherby Trust Company reported no remaining Inhibrx position as of Q1 2026 after selling out during the quarter.
  • Laird Norton Wetherby Trust Company sold 40,382 Inhibrx shares in Q1 2026, an estimated $3.19M.
  • Laird Norton Wetherby Trust Company first reported a position in Inhibrx in Q4 2025 and held it in 1 quarter.
  • Laird Norton Wetherby Trust Company's Inhibrx position peaked at $3.19M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Laird Norton Wetherby Trust Company's 13F filing for Q1 2026, filed 15 May 2026.